Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Ordinary Shares, par value GBP 0.001 per share
-
Shares outstanding
-
1,571,428,571
-
Total 13F shares
-
118,175,702
-
Share change
-
-11,705,618
-
Total reported value
-
$636,961,652
-
Put/Call ratio
-
64%
-
Price per share
-
$5.39
-
Number of holders
-
86
-
Value change
-
-$92,063,137
-
Number of buys
-
52
-
Number of sells
-
36
Institutional Holders of Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) as of Q4 2020
As of 31 Dec 2020,
Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) was held by
86 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
118,175,702 shares.
The largest 10 holders included
Matrix Capital Management Company, LP, NEA Management Company, LLC, BAILLIE GIFFORD & CO, BAKER BROS. ADVISORS LP, Capital World Investors, MORGAN STANLEY, Avoro Capital Advisors LLC, PFM Health Sciences, LP, RA CAPITAL MANAGEMENT, L.P., and CITADEL ADVISORS LLC.
This page lists
86
institutional shareholders reporting positions in this security
for the Q4 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.